ArticleCancer reports (Hoboken, N.J.)2026
Bladder Cancer Incidence Trends in the United States From 2000 to 2020.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer is one of the most common urogenital cancers globally. Here, we aimed to report the incidence trend of bladder cancer in the United States (US) over 2000-2020, by age, sex, race/ethnicity, and types using Surveillance, Epidemiology, and End Results (SEER).
methodsWe used SEER 22 data to calculate the age-standardized and delay-adjustment incidence rate of bladder cancer. Only individuals diagnosed with cancer and whose age at diagnosis was known were included in the study. A delay model was applied, adjusting for variables such as cancer site, registry, age group, race/ethnicity, and year of diagnosis. Using the Tiwari technique, the same database was also used to determine the age-standardized incidence rate (ASIR) of subtypes. The incidence data for 2020 were excluded from Joinpoint trends while displayed separately in illustrations.
resultsOver 2000-2019, most bladder cancer cases were urothelial carcinoma (92.99%), among non-Hispanic Whites (84.48%) and those aged 70 to 84 years (45.72%). There was a significant decrease in the ASIR of bladder cancer across all races/ethnicities in both sexes within all age groups (Average annual percent change (AAPC): -0.95%; [-1.06, -0.83] for men and -1.02% [-1.21, -0.84] for women) over 2000-2019. The incidence rates decreased by 6.23% during the COVID-19 pandemic. Also, the delay-adjusted incidence rate of bladder cancer increased with advancing age.
conclusionsDespite a decrease in ASIR of bladder cancer over 2000-2019, there are still a high number of incident cases, particularly among NHWs and the elderly. Future studies should investigate the underlying causes of bladder cancer incidence trends among demographic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.